PHILADELPHIA, Feb. 28 /PRNewswire-FirstCall/ -- Biofield Corp. announced that a leading company in Singapore has ordered the Biofield Diagnostic Electropotentials System and three cases of sensors representing enough complete sets for 600 exams. Biofield has already begun delivery, management believing that other orders will follow from this and other purchasers in Asia, Latin America and other parts of the world based upon existing marketing efforts. Biofield will also provide training and other services.
Each case contains sensors for tests on 200 female patients. Each test requires a set of 18 individual single-use sensors. A new set of single-use sensors must be used for each test. Depending on the test results, a female patient may need to undergo several tests a year.
Biofield believes that there are great opportunities for its technology in Singapore, which has 1.75 million women ages 15-64 years old.
The distributor is an industry leader in Singapore in biomedical engineering, which serves all the major medical centers and hospitals in Singapore. The end user is a nationally and internationally acclaimed institution in Singapore, which is recognized as an innovator for cutting edge technologies, including those in the biomedical science industry and medical device field, and for its commitment to public and community service.
Biofield Chairman James MacKay stated: “Having previously worked with Singapore on smartcard technologies, it is an honor and privilege to work again with the great country, people, and institutions of Singapore on such an important medical technology, which we hope can help save lives. We hope that this will help build our relationship with Singapore and will help build on our efforts to penetrate global markets in China, the Philippines and other parts of Asia as well as in Mexico and other parts of Latin America.”
About Biofield Corp.
Biofield Corp., a medical technology company, engages in the development and provision of noninvasive diagnostic medical devices to assist in detecting breast cancer. It offers Biofield Diagnostic System, a breast cancer diagnostic device, which employs single-use sensors to measure and analyze changes in cellular electrical charge distributions associated with the development of epithelial cancers, such as breast, ovaries, skin, prostate, and colon cancers. The company’s device is intended for palpable breast lesions, in women under 55 years of age. For more information, go to http://www.biofield.com.
SAFE HARBOR STATEMENT: Certain statements made in this press release should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management’s belief, as well as assumptions made by, and information currently available to, management pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified as such because the context of the statement will include words such as “believes,” “anticipates,” “appears,” “expects,” “should,” “may,” or words of similar import. Similarly, statements that describe the company’s future plans, objectives, estimates or goals are also forward-looking statements. Such statements may address future events and conditions concerning, among other matters, (i) the ability of the company to obtain sufficient funding in order to maintain operations, complete its FDA application and have its equipment manufactured and (ii) the granting of approval by the FDA of the company’s Breast Proliferation Detection System, which may not occur or, if it does, may not be timely. Additional factors which should be considered are set forth in the company’s Annual Report on Form 10-KSB and Quarterly Report on Form 10-QSB. Copies of such documents can be obtained from the EDGAR database Internet web site maintained by the Securities and Exchange Commission at http://www.sec.gov/edgarhp.htm. The company undertakes no obligation to release publicly the results of any revisions to its forward-looking statements that may be made in this press release to reflect events or circumstances occurring after the date of this press release.
CONTACT: Biofield Corp. Michael Yom, President myom@biofield.com 215.972.1717
Biofield Corp.
CONTACT: Michael Yom, President of Biofield Corp., +1-215-972-1717, ormyom@biofield.com
Web site: http://www.biofield.com//
